COVID-19

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty…

3 months ago

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone…

3 months ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

3 months ago

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

Charles W. Lapp, MD Charles W. Lapp, MD OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE…

3 months ago

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company…

3 months ago

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it…

3 months ago

Invivyd Announces CEO Transition

Jeremy Gowler appointed Interim CEOWALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on…

3 months ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

3 months ago

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population…

3 months ago

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in…

3 months ago